KR950009861B1 - Process for preparing 4h-1-benzopyran-4-one derivatives - Google Patents

Process for preparing 4h-1-benzopyran-4-one derivatives Download PDF

Info

Publication number
KR950009861B1
KR950009861B1 KR87003427A KR870003427A KR950009861B1 KR 950009861 B1 KR950009861 B1 KR 950009861B1 KR 87003427 A KR87003427 A KR 87003427A KR 870003427 A KR870003427 A KR 870003427A KR 950009861 B1 KR950009861 B1 KR 950009861B1
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
cycloalkyl
represents hydrogen
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR87003427A
Other languages
English (en)
Korean (ko)
Other versions
KR870010045A (ko
Inventor
Samba L Kattige
Ramchandra G Naik
Aftab D Dohadwalla Lakdawalla
N N Alihussei
Richard H Rupp
Souza Noel J De
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of KR870010045A publication Critical patent/KR870010045A/ko
Application granted granted Critical
Publication of KR950009861B1 publication Critical patent/KR950009861B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR87003427A 1986-04-11 1987-04-10 Process for preparing 4h-1-benzopyran-4-one derivatives Expired - Lifetime KR950009861B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3612337.4 1986-04-11
DE19863612337 DE3612337A1 (de) 1986-04-11 1986-04-11 4h-1-benzopyran-4-on-derivate, ein verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Publications (2)

Publication Number Publication Date
KR870010045A KR870010045A (ko) 1987-11-30
KR950009861B1 true KR950009861B1 (en) 1995-08-29

Family

ID=6298535

Family Applications (1)

Application Number Title Priority Date Filing Date
KR87003427A Expired - Lifetime KR950009861B1 (en) 1986-04-11 1987-04-10 Process for preparing 4h-1-benzopyran-4-one derivatives

Country Status (15)

Country Link
US (1) US4900727A (enExample)
EP (1) EP0241003B1 (enExample)
JP (1) JPH0686446B2 (enExample)
KR (1) KR950009861B1 (enExample)
AT (2) ATE95519T1 (enExample)
AU (1) AU602891B2 (enExample)
CA (1) CA1332238C (enExample)
DE (2) DE3612337A1 (enExample)
DK (1) DK169760B1 (enExample)
ES (1) ES2060582T3 (enExample)
IE (1) IE62244B1 (enExample)
IL (1) IL82149A (enExample)
IN (1) IN164232B (enExample)
PT (1) PT84654B (enExample)
ZA (1) ZA872555B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5278174A (en) * 1990-06-04 1994-01-11 Scios Nova, Inc. Sigma binding site agents
EP0508347A1 (en) * 1991-04-10 1992-10-14 Hoechst Aktiengesellschaft 5,7-Dihydroxy-2-methyl-8-[4-(3-hydroxy-1-(1-propyl)) piperidinyl]-4H-1-benzopyran-4-one, its preparation and its use
US6903084B2 (en) 1991-08-28 2005-06-07 Sterix Limited Steroid sulphatase inhibitors
US6476011B1 (en) 1991-08-28 2002-11-05 Sterix Limited Methods for introducing an estrogenic compound
US6011024A (en) 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
GB9604709D0 (en) * 1996-03-05 1996-05-01 Imperial College A compound
CZ285937B6 (cs) * 1992-01-16 1999-12-15 Hoechst Aktiengesellschaft Arylcykloalkylové deriváty, způsob přípravy těchto derivátů a jejich použití
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US6506792B1 (en) 1997-03-04 2003-01-14 Sterix Limited Compounds that inhibit oestrone sulphatase and/or aromatase and methods for making and using
US20060241173A1 (en) * 1996-02-16 2006-10-26 Sterix Ltd. Compound
US6087366A (en) * 1996-03-07 2000-07-11 The Trustees Of Columbia University In The City Of New York Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death
US5849733A (en) * 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US5908934A (en) * 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
DE19802449A1 (de) * 1998-01-23 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von (-)cis-3-Hydroxy-1-methyl-4-(2,4,6-trimethoxypyhenyl)-piperidin
GB9807779D0 (en) * 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
US6399633B1 (en) * 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (de) * 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
JP2003520797A (ja) * 2000-01-18 2003-07-08 アベンテイス・フアーマシユーチカルズ・インコーポレーテツド （−）−シス−２−（２−クロロフェニル）−５，７−ジヒドロキシ−８［４Ｒ−（３Ｓ−ヒドロキシ−１−メチル）ピペリジニル］−４Ｈ−１−ベンゾピラン−４−オンの偽多形体（ｐｓｅｕｄｏｐｏｌｙｍｏｒｐｈ）
US6576647B2 (en) 2000-01-18 2003-06-10 Aventis Pharmaceuticals Inc. Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one
US6821990B2 (en) * 2000-01-18 2004-11-23 Aventis Pharma Deutschland Gmbh Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5, 7-dihydroxy-8 [4R-(3S-hydroxy-1-M ethyl) piperidinyl]-4H-1-benzopyran-4-one
BR0107724A (pt) * 2000-01-18 2002-10-01 Aventis Pharma Inc Composto, processo para a preparação do mesmo, composição farmacêutica e, uso de um composto
FR2805538B1 (fr) * 2000-02-29 2006-08-04 Hoechst Marion Roussel Inc Nouveaux derives de flavones, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
KR100423899B1 (ko) 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
ATE471931T1 (de) 2002-04-17 2010-07-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
US7271193B2 (en) * 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
US7884127B2 (en) * 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
WO2004006865A2 (en) * 2002-07-17 2004-01-22 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (ja) * 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2005042697A2 (en) * 2003-10-06 2005-05-12 Cytokinetics, Inc. Compounds, compositions and methods
ATE447957T1 (de) * 2003-12-09 2009-11-15 Us Gov Health & Human Serv Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
EP1845973B1 (en) 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
MX2008016398A (es) 2006-06-21 2009-01-21 Piramal Life Sciences Ltd Compuestos enantiomericamente puros novedosos para el tratamiento de trastornos proliferativos.
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
TWI461194B (zh) 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
US8906953B2 (en) 2010-02-26 2014-12-09 Piramal Enterprises Limited Pyrrolidine substitute flavones for the treatment of inflammatory disorders
EP2580320B1 (en) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogramming of cells to a new fate
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
EP2984078B1 (en) 2013-04-10 2017-11-15 Council of Scientific & Industrial Research Novel chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders
WO2014170914A1 (en) 2013-04-17 2014-10-23 Council Of Scientific And Industrial Research Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof
TWI839690B (zh) 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
EP4183806A3 (en) 2014-11-12 2023-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
BR112017022666A8 (pt) 2015-04-20 2022-10-18 Tolero Pharmaceuticals Inc Preparando resposta à alvocidib por perfilamento mitocondrial
CN111349118B (zh) 2015-05-18 2023-08-22 住友制药肿瘤公司 具有增加的生物利用度的阿伏西地前药
RU2759963C2 (ru) 2015-08-03 2021-11-19 Сумитомо Даиниппон Фарма Онколоджи, Инк. Комбинированные терапии для лечения рака
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
JP6619519B2 (ja) 2016-12-19 2019-12-11 トレロ ファーマシューティカルズ， インコーポレイテッド プロファイリングペプチドおよび感受性プロファイリングのための方法
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
MX2021006544A (es) 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
WO2020213714A1 (ja) * 2019-04-18 2020-10-22 大日本住友製薬株式会社 シス－（－）－フロシノピペリドールの製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1223690A (en) * 1967-10-17 1971-03-03 Fisons Pharmaceuticals Ltd Substituted chromon-2-carboxylic acids
DE2731566A1 (de) * 1977-07-13 1979-02-01 Bayer Ag Verfahren zur herstellung von neuen chromon-derivaten, sowie ihre verwendung als pflanzenschutzmittel
GB2101115A (en) * 1980-10-23 1983-01-12 Pfizer Ltd Thromboxane synthetase inhibitors
DE3311005A1 (de) * 1983-03-25 1984-09-27 Bayer Ag, 5090 Leverkusen Chromon- und thiochromonsubstituierte 1,4-dihydropyridinderivate, mehrere verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE3329186A1 (de) * 1983-08-12 1985-02-21 Hoechst Ag, 6230 Frankfurt Chromonalkaloid, verfahren zu seiner isolierung aus dysoxylum binectariferum, und seine verwendung als arzneimittel
DE3445852A1 (de) * 1984-12-15 1986-06-19 Bayer Ag, 5090 Leverkusen Dihydropyridin-carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln

Also Published As

Publication number Publication date
AU7139787A (en) 1987-10-15
DE3787661D1 (de) 1993-11-11
JPH0686446B2 (ja) 1994-11-02
PT84654A (de) 1987-05-01
AT389875B (de) 1990-02-12
ATA260587A (de) 1989-07-15
DE3612337A1 (de) 1987-10-15
ATE95519T1 (de) 1993-10-15
PT84654B (pt) 1989-12-29
HK1006021A1 (en) 1999-02-05
DK185287A (da) 1987-10-12
AU602891B2 (en) 1990-11-01
IE870941L (en) 1987-10-11
KR870010045A (ko) 1987-11-30
EP0241003A2 (de) 1987-10-14
US4900727A (en) 1990-02-13
IE62244B1 (en) 1995-01-11
EP0241003B1 (de) 1993-10-06
IN164232B (enExample) 1989-02-04
CA1332238C (en) 1994-10-04
ZA872555B (en) 1987-11-25
DK169760B1 (da) 1995-02-20
DK185287D0 (da) 1987-04-10
JPS62242680A (ja) 1987-10-23
IL82149A0 (en) 1987-10-30
ES2060582T3 (es) 1994-12-01
EP0241003A3 (en) 1988-10-12
IL82149A (en) 1994-01-25

Similar Documents

Publication Publication Date Title
KR950009861B1 (en) Process for preparing 4h-1-benzopyran-4-one derivatives
PT99135A (pt) Processo para a preparacao de derivados de piperazina
IL113011A0 (en) R-mandelic acid salt of phenylpiperidine derivative
SE7605361L (sv) Sett att framstella nya n-substituerade fenylpiperazinderivat
ES8308543A1 (es) "procedimiento para la preparacion de nuevas 2-fenil-2-(piridiloxi)-etilaminas sustituidas".
PT93126A (pt) Processo para a preparacao de eteres carboxialquilicos da 2-amino-7- -hidroxitetralina
ES535411A0 (es) Procedimiento para preparar nuevos derivados del acido 4-fenil-4-oxo-buten-2-oico
ES461906A1 (es) Procedimiento para la obtencion de derivados benz-acilo-ben-zimidacol-2-carboxilicos.
ES523890A0 (es) Un procedimiento para preparar derivados de penem.
PT78918B (en) Process for preparing novel benzofuran derivatives
EP0346465A4 (en) 1-carboxy-1-vyniloxyiminoaminothiazole cephalosporing derivatives and process for their preparation.
IL72681A (en) 4-alkyl-5-haloimidazole-1-carboxylic acid esters and amides,their preparation and their use as nitrification inhibitors
FI873097A0 (fi) Foerfarande foer framstaellning av 1-metylaminokinolin-karboxylsyraderivat.
ES8504754A1 (es) Procedimiento para preparar la n-(3-trifluorometil fenil)-n-propargil-piperazina.
DK469285A (da) Thiadiazolderivater, der indvirker paa centralnervesystemet, fremgangsmaade til fremstilling deraf og midler indeholdende derivaterne
ZA924888B (en) Process for the synthesis of enantiomers of 3-aminochroman compounds
AT383811B (de) Verfahren zur herstellung von monoalkalisalzen von 7-amino-3-cephem-4-carbonsaeurederivaten
ES8303414A1 (es) Un procedimiento de preparacion de derivados de triazoloqui-nazolinona.
AT383599B (de) Verfahren zur herstellung von neuen racemischen und optisch aktiven e-homo-eburnan-derivaten sowievon saeureadditions-salzen derselben

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19870410

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19920313

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19870410

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19950522

Patent event code: PE09021S01D

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19950729

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19951128

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19951228

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19951228

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19980724

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 19990617

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20000621

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20010703

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20020703

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20030626

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20040616

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20050616

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20060619

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20060619

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term